DTH-Inducing Substance for HSV Lesion Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes simplex virus (HSV) infections, such as antiviral therapies, do not provide a cure and often require lifelong prophylactic use, with outbreaks still occurring frequently despite marginal symptom reduction.
Innovation Solution
Administering a substance that induces a delayed-type hypersensitivity (DTH) reaction locally at an HSV lesion to enhance the immune system's recognition and response to the virus, using substances like squaric acid dibutyl ester, diphenylcyclopropenone, or protein antigens to train T cells to reduce the severity and frequency of subsequent outbreaks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antiviral therapy is used to treat HSV infection, then symptom severity is marginally reduced, but outbreak frequency remains high and lifelong prophylaxis is required
Solution Approach 1:
The patent applies the principle of converting harm into benefit by using the viral outbreak itself (the harmful event) as a trigger for immunomodulatory treatment. The DTH-inducing substance is administered specifically during active outbreaks or prodromal phases, converting the harmful viral activation into an opportunity to stimulate and train the immune system. This approach transforms the recurring outbreak pattern from a purely negative event into a therapeutic window for immune enhancement, ultimately reducing both severity and frequency of future outbreaks without requiring continuous prophylaxis
2Productivity
If lifelong prophylactic antiviral therapy is administered, then outbreak frequency is reduced, but treatment duration and cumulative drug exposure increase
Solution Approach 1:
The patent implements periodic action by administering the DTH-inducing substance only during specific periods - namely during active outbreaks or prodromal phases - rather than continuously. This intermittent, event-driven treatment schedule allows the immune system to be periodically stimulated and trained without constant drug exposure. The approach maintains therapeutic effectiveness while dramatically reducing overall treatment duration and cumulative drug exposure compared to lifelong daily prophylaxis
Solution Approach 2:
The patent applies self-service by enabling the patient's own immune system to become the primary defense mechanism against HSV. Through repeated DTH stimulation during outbreaks, the immune system learns to recognize and respond more effectively to the virus. This empowers the body's natural defenses to control outbreak frequency and severity, reducing dependence on external antiviral medications and eliminating the need for continuous prophylactic treatment
3Reliability
If DTH-inducing substance is administered locally at HSV lesion, then immune response is strengthened, but local inflammation and discomfort increase during treatment
Solution Approach 1:
The patent applies preliminary action by administering the DTH-inducing substance at the earliest possible moment - during the prodromal phase or immediately at outbreak onset - before the lesion fully develops. This timing allows the immune system to be stimulated and trained during the critical early window when viral replication is active but before extensive tissue damage and severe inflammation occur. By acting preliminarily, the treatment maximizes immune training effectiveness while minimizing the duration and severity of adverse local reactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method strengthens the immune response, significantly reducing the frequency and severity of HSV outbreaks, potentially preventing future occurrences and reducing transmission, as demonstrated by reduced outbreak duration and increased time between outbreaks.
Implementation Method 1
administering a substance that induces a delayed-type hypersensitivity (DTH) reaction locally at an HSV lesion to enhance the immune system's recognition and response to the virus
Data Source
AI summary
A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.